[Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
Pain caused by bone metastases from carcinoma of the prostate are treated in particular by non-steroidal anti-inflammatory drugs and opioid-containing analgesics. In case of painful multilocular metastases, the use of osteotropic radionuclides which selectively irradiate the bone metastases while sparing healthy surrounding tissue offers an alternative. Owing to their favorable physical properties, rhenium-186 and samarium-153 are preferentially used. The rate of side effects--for the most part transient thrombocytopenia--is low, and the response rate is roughly 70 to 80% of the patients treated. Pain relief may last for between 1 and 6 months, with the option of multiple treatments. The prognosis of the disease is, however, not affected.
Klutmann
S
S
Abteilung für Nuklearmedizin, Krankenhaus Eppendorf der Universität Hamburg.
Bohuslavizki
K H
KH
D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009942:Organometallic Compounds; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D012211:Rhenium / Q000627:therapeutic use*; D016896:Treatment Outcome
D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid